AHK-Cu (Copper Tripeptide)

<p><strong>AHK-Cu (Alanyl-Histidyl-Lysine:Copper II complex)</strong> is a synthetic copper-chelating tripeptide structurally analogous to GHK-Cu (Glycyl-L-Histidyl-L-Lysine:copper) but distinguished by an alanine residue at the N-terminus instead of glycine. The substitution shifts the precise geometry of copper coordination and alters binding kinetics relative to the glycine-based parent, making AHK-Cu a useful comparator compound in studies designed to dissect how N-terminal residue identity modulates biological activity across the copper-tripeptide class.</p>

<h2>Mechanism of Action</h2>

<p>Copper tripeptides of the AHK/GHK class interact with cellular systems via two convergent routes. First, they serve as copper-delivery vectors: the His-Lys portion of the tripeptide chelates Cu²⁺ with high affinity, transporting it into the pericellular environment where copper is incorporated into cuproenzymes such as lysyl oxidase, superoxide dismutase (Cu/Zn-SOD), and ceruloplasmin. Second, the intact tripeptide or its fragments may interact directly with cell-surface receptors or extracellular matrix proteins to modulate gene expression independent of the copper cargo.</p>

<p>In the context of hair follicle biology, Uno and colleagues (2007, PMID 17703734) demonstrated that tripeptide-copper complexes including structural analogs of GHK-Cu influenced hair growth parameters in vitro, providing a mechanistic foundation for structure-activity relationship (SAR) studies using both GHK-Cu and AHK-Cu. The alanine-for-glycine substitution in AHK-Cu is expected to affect the binding constant for Cu²⁺, the metabolic stability of the tripeptide under proteolytic conditions, and possibly the spatial geometry of how the complex docks at relevant cellular targets. These differences make AHK-Cu a scientifically distinct tool rather than a simple equivalent of GHK-Cu.</p>

<p>Studies on the broader GHK-Cu class have identified downstream signaling through TGF-β modulation, VEGF upregulation, and antioxidant gene expression (Nrf2 pathway activation). Research using AHK-Cu would test whether the alanine substitution preserves, enhances, or attenuates these effects — a question with structural biology and drug-development relevance for anyone working on copper-tripeptide therapeutics or cosmeceutical actives.</p>

<h2>Research Applications</h2>

<ul> <li><strong>Structure-activity relationship (SAR) studies</strong> — comparing AHK-Cu directly to GHK-Cu in identical assay conditions to determine which N-terminal residue drives specific biological readouts (collagen synthesis, hair follicle proliferation, antioxidant gene expression, cell migration rates)</li> <li><strong>Trichological and hair follicle biology research</strong> — in vitro hair follicle organ culture models studying the influence of copper-tripeptide ligands on dermal papilla cell viability, keratinocyte proliferation, and anagen duration</li> <li><strong>Dermal collagen and extracellular matrix research</strong> — copper-dependent stimulation of lysyl oxidase activity, collagen crosslinking efficiency, and fibronectin/laminin deposition models</li> <li><strong>Copper biology and metallopeptide pharmacology</strong> — investigations into Cu²⁺ transport efficiency, intracellular copper availability, and copper chaperone protein interactions for compounds that differ only at the N-terminal amino acid</li> <li><strong>Antioxidant pathway research</strong> — studies examining whether AHK-Cu modulates superoxide dismutase activity or Nrf2-driven antioxidant gene transcription equivalently to GHK-Cu</li> <li><strong>Cosmeceutical and topical formulation science</strong> — stability studies, skin penetration kinetics (permeability coefficient comparisons between AHK-Cu and GHK-Cu across stratum corneum models), and preservative compatibility in peptide-containing topical preparations</li> <li><strong>Wound healing and tissue repair models</strong> — in vitro scratch-assay and transwell migration studies measuring whether AHK-Cu promotes cell migration into injury zones through mechanisms shared with or distinct from GHK-Cu</li> </ul>

<h2>Market Context</h2>

<p>AHK-Cu is a specialty comparator compound with limited commercial availability compared to the mainstream GHK-Cu. Peptides.SO currently tracks 2 active listings across suppliers, with pricing ranging from $0.90/mg to $175/mg. The 194× spread is a vial-format artifact: the $0.90/mg listing reflects a large-format bulk preparation (typically 1g–5g research-grade powder, priced per milligram of active content in the full order), while the $175/mg listing corresponds to a small research-quantity vial (commonly 2–5mg). Researchers procuring AHK-Cu should verify vial size, purity specification (HPLC ≥98%), and copper coordination form (whether the Cu²⁺ is pre-complexed or must be complexed separately) before comparing prices.</p>

<p>For researchers working on copper-tripeptide SAR studies, procuring both AHK-Cu and GHK-Cu from the same supplier in the same batch run reduces inter-preparation variability — a consideration that may justify the premium on supplier-matched paired offerings even when individual component pricing is higher than buying them from different sources.</p>

<h2>Key Differentiator vs. GHK-Cu</h2>

<ul> <li><strong>N-terminal residue:</strong> Alanine (AHK) vs. Glycine (GHK) — a non-polar, methyl-bearing residue vs. the smallest amino acid with no side chain</li> <li><strong>Cu²⁺ binding affinity:</strong> The alanine methyl group is expected to slightly alter the coordination geometry of the histidine-nitrogen and lysine-amine donor atoms in the Cu²⁺ complex</li> <li><strong>Metabolic stability:</strong> Alanine-terminated peptides may differ in aminopeptidase susceptibility versus glycine-terminated sequences</li> <li><strong>Receptor interaction:</strong> If intact-tripeptide signaling involves a receptor-binding domain, the N-terminal residue can affect docking orientation and binding strength</li> </ul>

<h2>Frequently Asked Questions</h2>

<p><strong>Is AHK-Cu the same as GHK-Cu?</strong><br/> No. Both are copper-chelating tripeptides studied for overlapping biological applications, but they differ at the N-terminal amino acid (alanine vs. glycine). This structural difference alters Cu²⁺ coordination geometry, potentially changes metabolic stability, and may produce different quantitative biological responses in the same assay model. AHK-Cu is used as a SAR comparator to GHK-Cu, not as a drop-in substitute.</p>

<p><strong>What research contexts require AHK-Cu specifically rather than GHK-Cu?</strong><br/> Studies specifically designed to investigate N-terminal residue effects on copper-tripeptide pharmacology — SAR programs in drug discovery, structure-guided optimization of topical copper-peptide actives, or academic investigations into metallopeptide binding thermodynamics — would require AHK-Cu as a distinct experimental condition.</p>

<p><strong>What analytical specifications should researchers look for?</strong><br/> Request HPLC purity ≥98% with a chromatogram at 214 nm (peptide bond absorption), mass spectrometry confirmation of the correct molecular ion for the Cu²⁺ complex ([AHK-Cu]²⁺ m/z ~170–175 depending on counter-ion), and endotoxin testing (&lt;1 EU/mg) if the compound will be used in cell-based or in vivo models.</p>

<p><strong>Is AHK-Cu studied in vivo or primarily in vitro?</strong><br/> The published literature on AHK-Cu specifically is limited; most mechanism-of-action data comes from GHK-Cu studies that structurally relate to the AHK-Cu class. AHK-Cu is primarily encountered in in vitro hair follicle, skin cell, and SAR studies. In vivo pharmacokinetic work with AHK-Cu specifically has not been widely published as of 2026.</p>

<h2>Cited Research</h2>

<ul> <li>Uno H, et al. "The effect of tripeptide-copper complex on human hair growth in vitro." <em>J Dermatol Sci.</em> 2007. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/17703734/" rel="noopener">17703734</a></li> <li>Pickart L, Vasquez-Soltero JM, Margolina A. "GHK-Cu may prevent oxidative stress in skin by regulating copper and modifying expression of numerous antioxidant genes." <em>Cosmetics.</em> 2015. doi: 10.3390/cosmetics2030236</li> <li>Pickart L, Margolina A. "Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data." <em>Int J Mol Sci.</em> 2018. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/29970841/" rel="noopener">29970841</a></li> </ul>

<p><em>For research purposes only. AHK-Cu is not approved for human or veterinary therapeutic use, is not a drug or dietary supplement, and has not been evaluated by the FDA or any regulatory authority for safety, efficacy, or purity in humans or animals outside controlled laboratory settings. All research must comply with applicable institutional and regulatory guidelines.</em></p>